** Shares of Stoke Therapeutics STOK.O rise 12.6% to $12.88
** The biotech says it has received U.S. FDA's "breakthrough therapy designation" for zorevunersen, its experimental drug for epileptic disorder Dravet Syndrome
** The FDA's tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need
** Breakthrough designation seems appropriate given disease modifying potential in a field of symptomatic treatments, brokerage BTIG says
** If approved, the drug could become the first disease modifying treatment for the disease
** Including session's moves, stock up 143.54% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。